Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia

Blood

Volumn 100, Issue 12, 2002, Pages 3877-3886

  Gratwohl, Alois ^a   Brand, Ronald ^b   Apperley, Jane ^c   Biezen, Anja V ^b   Bandini, Giuseppe ^d   Devergie, Agnes ^e   Schattenberg, Anton ^f   Frassoni, Francesco ^g   Guglielmi, Cesare ^h   Iacobelli, Simona ^h   Michallet, Mauricette ⁱ   Kolb, Hans Jochen ^j   Ruutu, Tapani ^k   Niederwieser, Dietger ^l  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LEIDEN UNIVERSITY   (Netherlands)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e SAINT LOUIS HOSPITAL   (France)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF GENOA   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^k HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^l UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; METHOTREXATE;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAZARD ASSESSMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0036893195     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V100.12.3877     Document Type: Article

References (43)

1. Thomas ED. Does bone marrow transplantation confer a normal life span? N Engl J Med. 1999; 341:50-51.
2. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: Clinical manifestation and therapy. Bone Marrow Transplant. 2001;28:121-129.
3. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: Pathobiology and management. Exp Hematol. 2001;29:259-277.
4. Vogelsang, GB. How I treat chronic graft-versus-host disease. Blood. 2001;97:1196-1201.
5. Ferrara JL. Pathogenesis of acute graft-versus-host disease: Cytokines and cellular effectors. J Hematother Stem Cell Res. 2000;9:299-306.
6. Marcellus DC, Vogelsang GB. Graft-versus-host disease. Curr Opin Oncol. 1997;9:131-138.
7. Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: Analysis of engraftment and acute graft-versus-host disease. Blood. 1996;88:795-802.
8. Antin JH. Acute graft-versus-host disease: Inflammation run amok? J Clin Invest. 2001;107:1497-1498.
9. Thomas ED, Storb R, Cliff RA, et al. Bone-marrow transplantation. N Engl J Med. 1975;292:895-902.
10. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068-1073.
11. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529-1533.
12. Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73: 1720-1728.
13. Fowler DH, Gress RE. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk Lymphoma. 2000;38:221-234.
14. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998;339:1177-1185.
15. Hansen JA, Yamamoto K, Petersdorf E, Sasazuki T. The role of HLA matching in hematopoietic cell transplantation. Rev Immunogenet. 1999;1:359-373.
16. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: Grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 1995;86:813-818.
17. Ringden O, Hermans J, Labopin M, Apperley J, Gorin NC, Gratwohl A. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Leuk Lymphoma. 1996;24:71-79.
18. Mathé G, Amiel JL, Schwarzenberg L, et al. Successful allogeneic bone marrow transplantation: Chimerism, induced specific tolerance and possible antileukemic effects. Blood. 1965;25:179-182.
19. Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukemia with x raxs and homologous bone marrow. Br Med J. 1956;2:626-627.
20. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-389.
21. Barrett J, Childs R. Non-myeloablative stem cell transplants. Br J Haematol. 2000;111:6-17.
22. Carella AM, Champlin R, Slavin S, McSweeney P, Storb R. Mini-allografts: Ongoing trials in humans. Bone Marrow Transplant. 2000;25:345-350.
23. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med. 2001;7:789-794.
24. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-4000.
25. Giralt SA, Kolb HJ. Donor lymphocyte infusions. Curr Opin Oncol. 1996;8:96-102.
26. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang. 1998; 74(suppl 2):321-329.
27. Barrett AJ, Ringden O, Zhang MJ, et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000;95:3323-3327.
28. Clift R, Goldman J, Gratwohl A, Horowitz M. Proposals for standardized reporting of results of bone marrow transplantation for leukemia. Bone Marrow Transplant. 1989;4:445-448.
29. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
30. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
31. Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A. Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant. 2001;27:899-916.
32. Passweg JR, Socie G, Hinterberger W, et al. Bone marrow transplantation for severe aplastic anemia: Has outcome improved? Blood. 1997;90: 858-864.
33. + chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant: An EBMT retrospective analysis. The Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood.2000;95:3328-3334.
34. Cornelissen JJ, Lowenberg B. Developments in T-cell depletion of allogeneic stem cell grafts. Curr Opin Hematol. 2000;7:348-352.
35. Tiberghien P, Herve P, Cahn JY. Graft T-cell depletion as a prerequisite for the modulation of alloreactivity after haematopoietic stem cell transplantation. Transfus Sci. 1997;18:327-336.
36. Sykes M. Chimerism and central tolerance. Curr Opin Immunol. 1996;8:694-703.
37. Weisdorf D, Hakke R, Blazar B, et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation. 1991;51:1197-1203.
38. Niederwieser D, Pepe M, Storb R, Witherspoon R, Longton G, Sullivan K. Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. Bone Marrow Transplant. 1989;4:151-156.
39. Al-Ghamdi H, Leisenring W, Bensinger WI, et al. A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest. Br J Haematol. 2001;113:461-469.
40. Kondo M, Kojima S, Horibe K, Kato K, Matsuyama T. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children. Bone Marrow Transplant. 2001; 27:727-730.
41. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344:1038-1042.
42. Druker BJ, Talpaz M, Resta BJ, et al. Efficacy and safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
43. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: Comparative analysis of unrelated versus matched sibling disease transplants. Blood. 2002;99:157-177.